Role of CA15.3 in Monitoring Hormone-Positive Breast Cancer Patients on Letrozole

Introduction to CA15.3 Monitoring

• The European Society for Medical Oncology recommends that CA15.3 should not be used for routine surveillance in patients on adjuvant letrozole after primary breast cancer treatment, but it is valuable for monitoring treatment response in patients with metastatic disease when combined with clinical examination and imaging 1, 2

When NOT to Use CA15.3

• The American Society of Clinical Oncology suggests that CA15.3 should not be ordered for routine follow-up monitoring in patients receiving adjuvant letrozole after curative treatment, as early detection of metastatic disease through tumor markers does not improve overall survival or quality of life 4
• The National Comprehensive Cancer Network states that CA15.3 has poor sensitivity for detecting locoregional recurrence 4

When TO Use CA15.3

• The European Society for Medical Oncology recommends using CA15.3 in conjunction with imaging, history, and physical examination to monitor treatment response in patients with metastatic hormone-positive breast cancer on letrozole 1, 2
• In patients without readily measurable disease by imaging, a rising CA15.3 can indicate treatment failure and prompt therapy change, according to the European Society for Medical Oncology 1, 2

Pretreatment Assessment

• The American Society of Clinical Oncology suggests that if CA15.3 exceeds a certain threshold at presentation, immediately search for metastases before finalizing any treatment plan 4
• The National Comprehensive Cancer Network recommends that the pretreatment CA15.3 concentration should be documented as the reference value for future comparison if metastatic recurrence is suspected 4

Critical Technical Requirements

• The College of American Pathologists states that all CA15.3 measurements for a given patient must be performed in the same laboratory using the same assay technique, as results vary significantly between different methods 1

Interpretation Guidelines

• The European Society for Medical Oncology indicates that CA15.3 levels that remain high despite letrozole treatment indicate treatment failure and very poor prognosis 4
• The American Society of Clinical Oncology notes that there is a correlation between tumor marker levels and disease response during treatment for metastases 4

Common Pitfalls to Avoid

• The National Comprehensive Cancer Network advises that CA15.3 should never be used as the sole criterion for changing letrozole therapy—always correlate with clinical and radiographic findings 4
• The European Society for Medical Oncology recommends avoiding multiple markers, as CA15.3 remains the reference standard for breast cancer, and adding multiple markers increases cost without improving clinical decision-making 4